Recent advances of antibody drug conjugates for clinical applications

Antibody drug conjugates (ADCs) normally compose of a humanized antibody and small molecular drug via a chemical linker. After decades of preclinical and clinical studies, a series of ADCs have been widely used for treating specific tumor types in the clinic such as brentuximab vedotin (Adcetris®) f...

Full description

Bibliographic Details
Main Authors:	Pengxuan Zhao, Yuebao Zhang, Wenqing Li, Christopher Jeanty, Guangya Xiang, Yizhou Dong
Format:	Article
Language:	English
Published:	Elsevier 2020-09-01
Series:	Acta Pharmaceutica Sinica B
Subjects:	Antibody drug conjugates Antibody Cytotoxic agents Linker Clinical application
Online Access:	http://www.sciencedirect.com/science/article/pii/S2211383520305554

id	doaj-eb045b7f8a54444aa85851359421c9db
record_format	Article
spelling	doaj-eb045b7f8a54444aa85851359421c9db2020-11-25T01:24:20ZengElsevierActa Pharmaceutica Sinica B2211-38352020-09-0110915891600Recent advances of antibody drug conjugates for clinical applicationsPengxuan Zhao0Yuebao Zhang1Wenqing Li2Christopher Jeanty3Guangya Xiang4Yizhou Dong5Division of Pharmaceutics & Pharmacology, College of Pharmacy, the Ohio State University, Columbus, OH 43210, USA; School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, ChinaDivision of Pharmaceutics & Pharmacology, College of Pharmacy, the Ohio State University, Columbus, OH 43210, USADivision of Pharmaceutics & Pharmacology, College of Pharmacy, the Ohio State University, Columbus, OH 43210, USADivision of Pharmaceutics & Pharmacology, College of Pharmacy, the Ohio State University, Columbus, OH 43210, USA; Neuroscience Program, College of Medicine & College of Arts and Sciences, the Ohio State University, Columbus, OH 43210, USASchool of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Corresponding authors.Division of Pharmaceutics & Pharmacology, College of Pharmacy, the Ohio State University, Columbus, OH 43210, USA; Department of Biomedical Engineering, the Ohio State University, Columbus, OH 43210, USA; The Center for Clinical and Translational Science, the Ohio State University, Columbus, OH 43210, USA; The Comprehensive Cancer Center, the Ohio State University, Columbus, OH 43210, USA; Dorothy M. Davis Heart & Lung Research Institute, the Ohio State University, Columbus, OH 43210, USA; Department of Radiation Oncology, the Ohio State University, Columbus, OH 43210, USA; Corresponding authors.Antibody drug conjugates (ADCs) normally compose of a humanized antibody and small molecular drug via a chemical linker. After decades of preclinical and clinical studies, a series of ADCs have been widely used for treating specific tumor types in the clinic such as brentuximab vedotin (Adcetris®) for relapsed Hodgkin's lymphoma and systemic anaplastic large cell lymphoma, gemtuzumab ozogamicin (Mylotarg®) for acute myeloid leukemia, ado-trastuzumab emtansine (Kadcyla®) for HER2-positive metastatic breast cancer, inotuzumab ozogamicin (Besponsa®) and most recently polatuzumab vedotin-piiq (Polivy®) for B cell malignancies. More than eighty ADCs have been investigated in different clinical stages from approximately six hundred clinical trials to date. This review summarizes the key elements of ADCs and highlights recent advances of ADCs, as well as important lessons learned from clinical data, and future directions.http://www.sciencedirect.com/science/article/pii/S2211383520305554Antibody drug conjugatesAntibodyCytotoxic agentsLinkerClinical application
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Pengxuan Zhao Yuebao Zhang Wenqing Li Christopher Jeanty Guangya Xiang Yizhou Dong
spellingShingle	Pengxuan Zhao Yuebao Zhang Wenqing Li Christopher Jeanty Guangya Xiang Yizhou Dong Recent advances of antibody drug conjugates for clinical applications Acta Pharmaceutica Sinica B Antibody drug conjugates Antibody Cytotoxic agents Linker Clinical application
author_facet	Pengxuan Zhao Yuebao Zhang Wenqing Li Christopher Jeanty Guangya Xiang Yizhou Dong
author_sort	Pengxuan Zhao
title	Recent advances of antibody drug conjugates for clinical applications
title_short	Recent advances of antibody drug conjugates for clinical applications
title_full	Recent advances of antibody drug conjugates for clinical applications
title_fullStr	Recent advances of antibody drug conjugates for clinical applications
title_full_unstemmed	Recent advances of antibody drug conjugates for clinical applications
title_sort	recent advances of antibody drug conjugates for clinical applications
publisher	Elsevier
series	Acta Pharmaceutica Sinica B
issn	2211-3835
publishDate	2020-09-01
description	Antibody drug conjugates (ADCs) normally compose of a humanized antibody and small molecular drug via a chemical linker. After decades of preclinical and clinical studies, a series of ADCs have been widely used for treating specific tumor types in the clinic such as brentuximab vedotin (Adcetris®) for relapsed Hodgkin's lymphoma and systemic anaplastic large cell lymphoma, gemtuzumab ozogamicin (Mylotarg®) for acute myeloid leukemia, ado-trastuzumab emtansine (Kadcyla®) for HER2-positive metastatic breast cancer, inotuzumab ozogamicin (Besponsa®) and most recently polatuzumab vedotin-piiq (Polivy®) for B cell malignancies. More than eighty ADCs have been investigated in different clinical stages from approximately six hundred clinical trials to date. This review summarizes the key elements of ADCs and highlights recent advances of ADCs, as well as important lessons learned from clinical data, and future directions.
topic	Antibody drug conjugates Antibody Cytotoxic agents Linker Clinical application
url	http://www.sciencedirect.com/science/article/pii/S2211383520305554
work_keys_str_mv	AT pengxuanzhao recentadvancesofantibodydrugconjugatesforclinicalapplications AT yuebaozhang recentadvancesofantibodydrugconjugatesforclinicalapplications AT wenqingli recentadvancesofantibodydrugconjugatesforclinicalapplications AT christopherjeanty recentadvancesofantibodydrugconjugatesforclinicalapplications AT guangyaxiang recentadvancesofantibodydrugconjugatesforclinicalapplications AT yizhoudong recentadvancesofantibodydrugconjugatesforclinicalapplications
_version_	1725117763485171712

Recent advances of antibody drug conjugates for clinical applications

Similar Items